Page last updated: 2024-12-06

isocytosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isocytosine is a synthetic nucleoside analog that has been shown to exhibit a variety of biological activities. It is a potent inhibitor of DNA polymerase, and it has also been shown to have antiviral and antitumor activity. Isocytosine has been studied as a potential therapeutic agent for a variety of diseases, including cancer, viral infections, and autoimmune disorders. Isocytosine is synthesized by a variety of methods, including chemical synthesis and enzymatic synthesis. The most common method of synthesis is the chemical synthesis of isocytosine from cytosine. Isocytosine is studied for its potential therapeutic effects. It has been shown to inhibit the growth of cancer cells and to have antiviral activity. Isocytosine is also being investigated as a potential treatment for autoimmune disorders. '

2-amino-4-hydroxypyrimidine : An aminopyrimidine in which the pyrimidine ring bears amino and hydroxy substituents at positions 2 and 4, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID66950
CHEMBL ID56260
CHEBI ID55502
SCHEMBL ID4825
SCHEMBL ID8852643
MeSH IDM0246035

Synonyms (90)

Synonym
2-amino-4-oxypyrimidine
nsc49118
nsc-49118
4(1h)-pyrimidinone, 2-amino-
2-amino-4-pyrimdinol
2-amino-4-pyrimidone
4-pyrimidinol, 2-amino-
isocytosine
2-amino-4-hydroxypyrimidine
108-53-2
2-amino-1h-pyrimidin-4-one
2-aminouracil
2-aminopyrimidin-4(1h)-one
AC-907/25004299
2-amino-4-pyrimidol
2-aminopyrimidin-4-ol
2-aminopyrimidin-4(3h)-one
4(3h)-pyrimidinone, 2-amino-
inchi=1/c4h5n3o/c5-4-6-2-1-3(8)7-4/h1-2h,(h3,5,6,7,8
2-amino-3h-pyrimidin-4-one
2-amino-1h-pyrimidin-6-one
isocytosine, >=99%
CHEMBL56260 ,
chebi:55502 ,
FT-0693428
674-97-5
isocytosine (van)
ai3-52238
einecs 203-592-0
nsc 49118
AKOS010519665
2-amino-6-hydroxypyrimidine
2-amino-4-pyrimidinol
AKOS016034248
bdbm50405230
100643-25-2
FT-0602441
AM20080033
PB29007
145358-63-0
EPITOPE ID:119698
AKOS015854926
S6256
2-amino-1,4-dihydropyrimidin-4-one
SCHEMBL4825
2-amino-3,4-dihydropyrimidin-4-one
SCHEMBL8852643
mfcd00057557
SY013450
W-200787
DS-0256
4-pyrimidinol, 2-amino- (9ci)
2-amino-4(1h)-pyrimidinone #
I0814
2-amino-4(1h)-pyrimidinone
DTXSID00148350
CS-W002272
155831-94-0
155831-92-8
155831-93-9
4-pyrimidinol, 1,2-dihydro-2-imino- (9ci)
4(1h)-pyrimidinone, 2,3-dihydro-2-imino- (9ci)
4-pyrimidinol, 2,3-dihydro-2-imino- (9ci)
2-imino-6-pyrimidinon
107646-85-5
4(1h)-pyrimidinone, 2,3-dihydro-2-imino-, (z)- (9ci)
4(1h)-pyrimidinone, 2,3-dihydro-2-imino-, (e)- (9ci)
107646-87-7
4(1h)-pyrimidinone,2,3-dihydro-2-imino-
176773-02-7
176773-01-6
4-pyrimidinol, 1,2-dihydro-2-imino-, (z)- (9ci)
176773-00-5
4-pyrimidinol, 2,3-dihydro-2-imino-, (e)- (9ci)
4-pyrimidinol, 2,3-dihydro-2-imino-, (z)- (9ci)
4-pyrimidinol,2-amino-
1,4-dihydro-2-amino-4-oxopyrimidine
mfcd00023256
Q10859790
EN300-64686
SB10360
HY-W002272
H10127
isocytosin
2-amino-4-hydroxypyrimidine, 2-aminouracil
SB57721
iso cytosine
CS-0166939
4(1h)-pyrimidinone,2,3-dihydro-2-imino-,(e)-(9ci)
Z801295650
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
pyrimidine nucleobaseA nucleobase whose skeleton is derived from pyrimidine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydropteroate synthaseEscherichia coli K-12IC50 (µMol)500.00002.50003.60004.7000AID55870
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)500.00000.00040.908610.0000AID55870
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
response to xenobiotic stimulusDihydropteroate synthaseEscherichia coli K-12
folic acid biosynthetic processDihydropteroate synthaseEscherichia coli K-12
folic acid-containing compound biosynthetic processDihydropteroate synthaseEscherichia coli K-12
tetrahydrofolate biosynthetic processDihydropteroate synthaseEscherichia coli K-12
folic acid biosynthetic processDihydropteroate synthaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
dihydropteroate synthase activityDihydropteroate synthaseEscherichia coli K-12
transferase activityDihydropteroate synthaseEscherichia coli K-12
metal ion bindingDihydropteroate synthaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytoplasmDihydropteroate synthaseEscherichia coli K-12
cytosolDihydropteroate synthaseEscherichia coli K-12
cytosolDihydropteroate synthaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1530048Inhibition of Streptococcus pyogenes SrtA deltaN81 mutant expressed in Escherichia coli BL21(DE3) at 100 uM using Abz-LPETA-Dap(Dnp) as substrate preincubated for 10 mins followed by substrate addition measured every min for 2.5 hrs by fluorimetric assay 2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of potential antivirulence agents by substitution-oriented screening for inhibitors of Streptococcus pyogenes sortase A.
AID55870In vitro inhibition of dihydropteroate synthase from Escherichia coli.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Monocyclic pteridine analogues. Inhibition of Escherichia coli dihydropteroate synthase by 6-amino-5-nitrosoisocytosines.
AID55872In vitro inhibition of dihydropteroate synthase from Escherichia coli.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Monocyclic pteridine analogues. Inhibition of Escherichia coli dihydropteroate synthase by 6-amino-5-nitrosoisocytosines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (13.33)18.7374
1990's6 (13.33)18.2507
2000's12 (26.67)29.6817
2010's16 (35.56)24.3611
2020's5 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.70 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]